Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL28512738 | 0.84 | LMNA (0.56) | CA5ACA5BLMNAALDH1A1THRB | |
| Glycerin SCHEMBL7035160 | 0.84 | LMNA (0.56) | CA5ACA5BLMNAALDH1A1THRB | |
| Glycerin SCHEMBL2220986 | 0.84 | LMNA (0.56) | CA5ACA5BLMNAALDH1A1THRB | |
| Glycerin SCHEMBL854170 | 0.84 | LMNA (0.56) | CA5ACA5BLMNAALDH1A1THRB | |
| Glycerin SCHEMBL124052 | 0.84 | LMNA (0.56) | CA5ACA5BLMNAALDH1A1THRB | |
| Glycerin SCHEMBL8430202 | 0.84 | LMNA (0.56) | CA5ACA5BLMNAALDH1A1THRB | |
| Glycerin SCHEMBL711997 | 0.84 | LMNA (0.56) | CA5ACA5BLMNAALDH1A1THRB | |
| Glycerin SCHEMBL21352472 | 0.81 | LMNA (0.53) | CA5ACA5BLMNAALDH1A1THRB | |
| Glycerin SCHEMBL21799190 | 0.81 | LMNA (0.53) | CA5ACA5BLMNAALDH1A1THRB | |
| SCHEMBL2945693 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797100-A4 | NITRATE ESTERS AND THEIR USE FOR MITIGATING CELLULAR DAMAGE | UNIV KINGSTON (CA) | 2009-05-13 | — | — | EP | disclosed |
| EP-1797100-A1 | NITRATE ESTERS AND THEIR USE FOR MITIGATING CELLULAR DAMAGE | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006029532-A1 | NITRATE ESTERS AND THEIR USE FOR MITIGATING CELLULAR DAMAGE | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-03-23 | — | — | WO | disclosed |
| US-20050137191-A1 | Nitrate esters and their use for mitigating cellular damage | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2005-06-23 | — | — | US | disclosed |
| EP-0915842-B1 | NITRATE ESTERS AND THEIR USE FOR NEUROLOGICAL CONDITIONS | UNIV KINGSTON (CA) | 2004-04-28 | — | — | EP | disclosed |
| EP-0915842-A1 | NITRATE ESTERS AND THEIR USE FOR NEUROLOGICAL CONDITIONS | Queen's University at Kingston (CA) | 1999-05-19 | — | — | EP | disclosed |
| US-5883122-A | NEUROPROTECTIVE AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1999-03-16 | — | — | US | disclosed |
| WO-1997046521-A1 | NITRATE ESTERS AND THEIR USE FOR NEUROLOGICAL CONDITIONS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137191-A1 | Nitrate esters and their use for mitigating cellular damage | NLN, NOS1, NOS3 | CA5A 1702/4885CA5B 1479/4885LMNA 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.